Patients with the inherited disorder hereditary angioedema (HAE) suffer from episodes of
soft tissue swelling due to excessive bradykinin production. In most cases, dysregulation of …

Tranexamic acid (TA) is an antifibrinolytic agent, increasingly recognized as being of utility
for a wide variety of skin diseases. We review the evidence supporting the use of TA for a …

Tranexamic acid (TXA) is an antifibrinolytic agent which inhibits conversion of plasminogen
to plasmin, a key step in kallikrein activation and bradykinin formation. Tranexamic acid is …

Introduction: Angioedema is a rare but potentially life-threatening adverse effect associated
with the use of angiotensin-converting enzyme (ACE) inhibitors. Various therapies, including …

Tranexamic acid (TXA) is a synthetic lysine analogue that is well known as antifibrinolytic
agent. It can reduce blood loss in clinical use, especially in conditions where fibrinolysis or …

Angioedema is a rare adverse effect of the commonly used angiotensin‐converting enzyme
inhibitors (ACE i) and is reported to occur with a prevalence of 0.1%‐0.7%. Although most …

Angiotensin-converting enzyme (ACE) inhibitors are the leading cause of drug-induced
angioedema in the United States because they are so widely prescribed. Patients most …

Tranexamic acid is a synthetic derivative of the amino acid lysine, an antifibrinolytic that is
primarily used to reduce bleeding in surgery, trauma, and dental procedures. Its anti …

Background Angiotensin converting enzyme inhibitor-induced angioedema is a major cause
of angioedema-related hospitalizations each year. Common swelling predilection sites …

Background Given the heterogeneity of etiologies, pathophysiology, and presentation of
angioedema, variations in clinical outcomes, such as intubation and hospital readmissions …